| Formulary Chapter 5: Infections - Full Chapter
|
| 05.03.01 |
HIV infection |
|
|
| 05.03.01 |
Antiviral medications |
|
|
Abacavir (Ziagen®)
|
Formulary
|
Tablets: 300mg
Oral solution: 20mg/ml
|
|
|
Abacavir and Lamivudine (Kivexa®)
|
Formulary
|
Tablets: 600mg/300mg
|
|
|
Abacavir,Lamivudine and Zidovudine (Trizivir®)
|
Formulary
|
Tablets: 150/300/300mg
|
|
|
Atazanavir (Reyataz®)
|
Formulary
|
Capsules: 150mg, 200mg, 300mg
|
|
|
Atazanavir sulfate and cobicistat (Evotaz®)
|
Formulary
|
Tablets: 300mg/150mg
|
|
|
Cobicistat (Tybost®)
|
Formulary
|
Tablets: 150mg
|
|
|
Darunavir (Prezista®)
|
Formulary
|
Tablets: 75mg, 150mg, 400mg, 600mg, 800mg
Oral suspension: 100mg/ml
|
|
|
Darunavir and cobicistat (Rezolsta®)
|
Formulary
|
Tablets: 800mg/150mg
|
|
|
Didanosine (Videx®)
|
Formulary
|
Chewable tablets: 25mg
E/C capsules: 125mg, 200mg, 250mg, 400mg
|
|
|
Dolutegravir (Tivicay®)
|
Formulary
|
Tablets: 10mg, 25mg, 50mg
|
|
|
Dolutegravir, abacavir and lamivudine (Triumeq®)
|
Formulary
|
Tablets: 50mg/600mg/300mg
|
|
|
Efavirenz (Sustiva®)
|
Formulary
|
Tablets: 600mg
Capsules: 50mg, 100mg 200mg
|
|
|
Elvitegravir (Vitekta)
|
Formulary
|
Tablets: 85mg, 150mg
|
|
|
Emtricitabine (Emtriva®)
|
Formulary
|
Capsules: 200mg
Oral solution: 10mg/ml
|
|
|
Emtricitabine and tenofovir (Descovy®)
|
Formulary
|
Tablets: 200mg/10mg
Tablets: 200mg/25mg
|
|
|
Emtricitabine rilpivirine and tenofovir (Eviplera®)
|
Formulary
|
Tablets: 200mg/25mg/245mg
|
|
|
Emtricitabine, rilpivirine and tenofovir (Odefsey®)
|
Formulary
|
Tablets: 200mg/25mg/25mg
|
|
|
Enfuvirtide (Fuzeon®)
|
Formulary
|
Powder and solvent for solution for injection vials: 108mg
|
|
|
Etravirine (Intelence®)
|
Formulary
|
Tablets: 25mg, 100mg, 200mg
|
|
|
Fosamprenavir (Telzir®)
|
Formulary
|
Tablets: 700mg
Oral suspension: 50mg/ml
|
|
|
Indinavir (Crixivan®)
|
Formulary
|
Capsules: 200mg
|
|
|
Lamivudine (Epivir®, Zeffix®)
|
Formulary
|
Tablets: 100mg, 150mg, 300mg (brands include Epivir®, Zeffix®)
Oral solution: 50mg/5ml (Epivir®)
|
|
|
Lopinavir and ritonavir (Kaletra®)
|
Formulary
|
Tablets: 100mg/25mg, 200mg/50mg
Oral solution: 400mg/100mg in 5ml
|
|
|
Maraviroc (Celsentri®)
|
Formulary
|
Tablets: 150mg, 300mg
|
|
|
Nevirapine (Viramune®)
|
Formulary
|
Oral suspension: 10mg/1ml
MR tablets: 100mg, 400mg
Tablets: 200mg
|
|
|
Raltegravir (Isentress ®)
|
Formulary
|
Tablets: 400mg
|
|
|
Rilpivirine hydrochloride (Edurant®)
|
Formulary
|
Tablets: 25mg
|
|
|
Ritonavir (Norvir®)
|
Formulary
|
Tablets: 100mg
|
|
|
Saquinavir (Invirase®)
|
Formulary
|
Tablets: 500mg
|
|
|
Stavudine (Zerit®)
|
Formulary
|
Capsules: 20mg, 30mg, 40mg
Oral solution: 1mg/ml
|
|
|
Tenofovir and emtricitabine (Truvada®)
|
Formulary
|
Tablets containing: 200mg of emtricitabine and 245mg of tenofovir disoproxil (equivalent to 300mg of tenofovir disoproxil fumarate or 136mg of tenofovir)
|
|
|
Tenofovir disoproxil (Viread®)
|
Formulary
|
Tablets: 123mg, 163mg, 204mg, 245mg (as tenofovir disoproxil fumarate)
|
|
|
Tenofovir Disproxil
|
Formulary
|
Tablets: 245mg
Granules (sugar-free): 33mg/1g (7.5g contains approximately 245mg tenofovir disoproxil)
|
 NICE CG165: Hepatitis B (chronic) - incorporates TA173
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
|
Tenofovir, cobicistat, elvitegravir and emtricitabine (Stribild®)
|
Formulary
|
Tablets: 150mg/150mg/200mg/245mg
|
|
|
Tenofovir, efavirenz and emtricitabine (Atripla®)
|
Formulary
|
Tablets: 600mg/200mg/245mg
|
|
|
Tipranavir (Aptivus®)
|
Formulary
|
Oral solution: 100mg/ml
Capsules: 250mg
|
|
|
Zidovudine (Retrovir®)
|
Formulary
|
Capsules: 100mg, 250mg
Oral solution: 50mg/5ml
Solution for infusion: 200mg/20ml
|
|
|
Zidovudine and lamivudine (Combivir®)
|
Formulary
|
Tablets: 150mg/300mg
|
|
|
| 05.03.01 |
Protease inhibitors |
|
|
| 05.03.01 |
Non-nucleoside reverse transcriptase inhibitors |
|
|
| 05.03.01 |
Other antiretrovirals |
|
|
| 05.03.01 |
Pharmacokinetic enhancers of antiretrovirals |
|
|
| .... |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist.
These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.
|
|
These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care.
For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug.
Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.
|
|
Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case. |
|
These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care.
N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN. |
|
|
|
